Vanguard Capital Management’s bioAffinity Technologies BIAF Stock Holding History
Bought
Maintained
Sold
Other funds holding BIAF
RMI
Vanguard Capital Management's BIAF Position: Q3 2026 in Review
Vanguard Capital Management reduced its bioAffinity Technologies (BIAF) stake by 0.05% in Q3 2026, selling an estimated $17 and leaving 3,701 shares worth $24.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3966.
Vanguard Capital Management first reported a position in BIAF in Q1 2026 and has held it in 3 quarters since. The position peaked at $213K in Q1 2026. 14 funds tracked by Wall St. Rank hold BIAF as of Q3 2026.
- Vanguard Capital Management held 3,701 shares of bioAffinity Technologies worth $24.3K as of Q3 2026.
- Vanguard Capital Management sold 2 bioAffinity Technologies shares in Q3 2026, an estimated $17.
- bioAffinity Technologies made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3966 holding.
- Vanguard Capital Management first reported a position in bioAffinity Technologies in Q1 2026 and has held it in 3 quarters since.
- Vanguard Capital Management's bioAffinity Technologies position peaked at $213K in Q1 2026.
- 14 funds tracked by Wall St. Rank held bioAffinity Technologies as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.